Warner Pharmaceutical announced that the company has received the "Drug Supplementary Application Approval Notice" issued by the National Medical Products Administration regarding the change of the holder of the marketing authorization for Benidipine Hydrochloride tablets. This pharmaceutical is suitable for primary hypertension and angina. The company has become the holder of the marketing authorization for Benidipine Hydrochloride tablets, further enriching the variety of the company's formulated products and has positive significance for optimizing the company's product structure. The change of the holder of the marketing authorization for this pharmaceutical will not have a significant impact on the company's recent performance. Future sales may be influenced by various factors such as policy changes, market demand, competition in the market of similar pharmaceuticals, etc., which are uncertain.